BMI View: As Norway's economy continues to rebalance away from oil dependence, industrial policy
aimed at boosting production capacity and research in the health sector is set to strengthen. In fact,
Norway's government has identified the life sciences and biomedica ..."
BMI View: Norway's life sciences and biomedical research base will continue to develop at a sustained
pace, which will enhance investment opportunities over the medium to long term. Meanwhile, Norway's
ongoing expansionary fiscal policy, as well as market growth funda ..."
BMI View: Norwegian macroeconomic and policy trends continue to support our outlook for stable longterm
growth in the pharmaceutical and healthcare sector. The government will continue to account for the
largest share of healthcare spending over the forecast period. H ..."
BMI View: Norway's 2016 fiscal stimulus is expected to be positive in terms of supporting the
pharmaceutical and healthcare sector growth trajectory. Over the long term, policies aimed at promoting
economic diversification away from energy exports are set to benefit t ..."
BMI View: Norway's pharmaceuticals and healthcare markets will continue to expand over the next
decade, with patented medicines to continue to account for the majority of the drug market, reflecting an
ageing population and the adoption of innovative treatments. Meanw ..."
BMI View: Against a backdrop of high per capita spending on medicines, an ageing population and
sustained growth in healthcare expenditure, Norway is expected to remain among the seven most attractive
markets in Western Europe to drug manufacturers in the foreseeable ..."
BMI View: Norway's epidemiological profile will continue to be attractive to manufacturers of medicines
for non-communicable diseases. Despite the relative rapid uptake of innovative pharmaceuticals, the
burden of chronic conditions will only decrease slightly over th ..."
BMI View: Despite the forecasted decline in the burden of disease in Norway over the next two decades,
the anticipated growth of Norway's ageing population is to have an unprecedented impact on the demand
for healthcare. The elderly require more medical check-ups and ..."
BMI View: While the Norwegian government's pro-generic stance will continue to support growth in the
country's off-patent medicines market, we highlight that the loss of market value in the patented drugs
sector will not translate into an equivalent gain for the gener ..."
BMI View: An ageing population and the subsequent increased consumption of high-value prescription
medicines for the treatment of long-term illnesses will result in rising demand for reimbursed medicines in
Norway. In the long term, we believe this will result in stro ..."